KRAS and cancer: Recent data from limited number of KRAS G12C mutant cancer patients indeed show accumulation of secondary KRAS mutations in codons 12, 13, 61, 68, 95 and 96 upon treatment with G12C inhibitor adagrasib (MRTX849)32,33.